Advertisement
Screener

OMEROS CORP (OMER) Operating Lease Right-of-Use Assets

2.8 / 5 stars · 68/120 Roast Me

OMEROS CORP Operating Lease Right-of-Use Assets

OMEROS CORP (OMER) had Operating Lease Right-of-Use Assets of $8.28 million as of 2026-06-30, per its 10-Q filed 2026-08-12.

Financial Statements › Balance Sheet › Assets › Assets, Noncurrent

us-gaap:OperatingLeaseRightOfUseAsset · last filed 2026-08-12

  • 2026-06-30: Operating Lease, Right-of-Use Asset $8.28M.
  • 2026-03-31: Operating Lease, Right-of-Use Asset $9.52M.
  • 2025-12-31: Operating Lease, Right-of-Use Asset $10.71M.
  • 2025-09-30: Operating Lease, Right-of-Use Asset $11.81M.
Period endOperating Lease, Right-of-Use Asset
2026-06-30$8.28M
10-Q · filed 2026-08-12
2026-03-31$9.52M
10-Q · filed 2026-05-13
2025-12-31$10.71M
10-Q · filed 2026-08-12
2025-09-30$11.81M
10-Q · filed 2025-11-13
2025-06-30$12.89M
10-Q · filed 2025-08-14
2025-03-31$13.95M
10-Q · filed 2025-05-15
2024-12-31$14.96M
10-K · filed 2026-03-31
2024-09-30$15.93M
10-Q · filed 2024-11-13
2024-06-30$16.87M
10-Q · filed 2024-08-07
2024-03-31$17.77M
10-Q · filed 2024-05-15
2023-12-31$18.63M
10-K · filed 2025-03-31
2023-09-30$19.46M
10-Q · filed 2023-11-09
2023-06-30$20.26M
10-Q · filed 2023-08-09
2023-03-31$21.02M
10-Q · filed 2023-05-09
2022-12-31$21.76M
10-K · filed 2024-04-01
2022-09-30$22.46M
10-Q · filed 2022-11-09
2022-06-30$23.13M
10-Q · filed 2022-08-09
2022-03-31$22.91M
10-Q · filed 2022-05-10
2021-12-31$28.28M
10-K · filed 2023-03-13
2021-09-30$29.04M
10-Q · filed 2021-11-09
2021-06-30$29.82M
10-Q · filed 2021-08-09
2021-03-31$24.99M
10-Q · filed 2021-05-10
2020-12-31$25.53M
10-K · filed 2022-03-01
2020-09-30$26.12M
10-Q · filed 2020-11-09
2020-06-30$26.60M
10-Q · filed 2020-08-10
2020-03-31$27.08M
10-Q · filed 2020-05-11
2019-12-31$27.08M
10-K · filed 2021-03-01
2019-09-30$21.30M
10-Q · filed 2019-11-12
2019-06-30$17.32M
10-Q · filed 2019-08-08
2019-03-31$17.51M
10-Q · filed 2019-05-09
2018-12-31$0.00
10-Q · filed 2019-05-09

Similar stocks

Stock NameCountryMarket CapPE Ratio
Ultragenyx Pharmaceutical Inc. (RARE)United States$1.456B-5.62
ArriVent BioPharma, Inc. (AVBP)United States$1.485B-10.25
Innoviva, Inc. (INVA)United States$1.493B4.62
Oric Pharmaceuticals, Inc. (ORIC)United States$1.367B-8.00
ANAPTYSBIO, INC (ANAB)United States$1.546B-60.20
Kailera Therapeutics, Inc. (KLRA)United States$1.552B
Kardigan, Inc. (KARD)United States$1.346B
Tyra Biosciences, Inc. (TYRA)United States$1.337B-12.83
Bicara Therapeutics Inc. (BCAX)United States$1.309B-10.55
Syndax Pharmaceuticals Inc (SNDX)United States$1.606B-8.82